Enokitake (Flammulina velutipes / Flammulina filiformis): A Comprehensive Reference
1. Identity and Nomenclature
1.1 Taxonomic Status and Scientific Names
Enokitake is an edible species of gilled mushroom in the family Physalacriaceae, commonly known as velvet shank, enoki, winter mushroom, or golden needle mushroom. For much of modern mycological history, both the East Asian cultivated form and the European/North American wild form were classified together as Flammulina velutipes (W. Curtis : Fr.) Singer. The species was originally described from England by botanist William Curtis in 1782 as Agaricus velutipes, and was later transferred to the genus Flammulina by Rolf Singer in 1951.
A significant taxonomic revision now distinguishes two separate species. Until recently, F. velutipes was considered to be conspecific with the Asian F. filiformis, cultivated for food as "enokitake" or "golden needle mushroom," but DNA sequencing shows that the two are distinct. The name enoki or enokitake often refers to the wild form but is more accurately applied to the cultivated Asian strains, which a 2018 phylogenetic study reclassified as the separate species Flammulina filiformis based on molecular evidence from ITS, tef1-α, rpb2, and mating-type loci, distinguishing European/North American F. velutipes from East Asian populations. This revision resolved long-standing taxonomic confusion, confirming F. filiformis as the true identity of the commercially grown winter mushroom in East Asia.
Fungi from the Flammulina genus are known to contain a number of bioactive compounds that have potential therapeutic and industrial applications, but most of this type of research would have focused on F. filiformis instead of F. velutipes due to the above-mentioned taxonomic confusion. Throughout the scientific literature predating 2018, the name "Flammulina velutipes" is routinely used to describe what is now understood to be the East Asian cultivated form, F. filiformis. The present article treats findings under the older nomenclature as referring to the enokitake organism unless otherwise noted.
Flammulina velutipes belongs to the Marasmioid clade, part of the order Agaricales, which includes the model mushroom Schizophyllum commune and the edible mushroom Lentinula edodes (Shiitake). F. velutipes is further classified in the family Physalacriaceae, together with Armillaria species (honey fungus), which encompass edible fungi and plant pathogens.
1.2 Common Names and Etymology
The name "enoki" comes from the Japanese word for the Chinese hackberry tree (enokitake), where these mushrooms frequently grow in the wild. Other names include golden needle mushrooms, winter mushrooms, or lily mushrooms. In Chinese it is known as jīn zhēn gū (金针菇), and in Korean as 팽이버섯 (paengi beosut).
1.3 Natural Source and Ecology
Native to China, Japan, and Korea, enoki mushrooms grow naturally on the stumps and trunks of Chinese hackberry trees, ash trees, mulberry trees, and persimmon trees. The enokitake mushroom also grows on the dead wood of Betula platyphylla, Broussonetia papyrifera, Dipentodon sinicus, Neolitsea species, Salix species, and other broad-leaved trees. It is a wood-rotting saprotroph that fruits preferentially in cold weather, hence one of its common names.
1.4 Morphology: Wild Versus Cultivated Forms
In the wild, enoki mushrooms appear quite different — with shorter stems, larger caps, and a yellow-brown or orange color — compared to the cultivated white variety most commonly found in markets today. The cultivated version of enoki mushrooms is grown in dark environments with high carbon dioxide levels, which contributes to their characteristic long, thin, white appearance. Growers observed that by leaving the mushroom in a closed room, without light and with a high concentration of carbon dioxide, the mushroom grew without the characteristic orange colour of its cap, which became noticeably smaller and white, softer for cooking and more attractive to the eye.
1.5 Common Preparations and Forms
Cultivated enokitake mushrooms are sold both fresh and canned. The fungus has a crisp texture and is a common ingredient in soups, especially in East Asian cuisine, although it can be used for salads and other types of dishes as well. As a dietary supplement, enokitake is available in the form of dried powders, standardised capsules, and liquid extracts. It can be cultivated on various substrates, including sawdust, wheat straw, and paddy straw.
2. Traditional and Historical Use
2.1 East Asian Cultivation and Culinary History
Commonly known as enokitake, velvet shank, golden needle mushroom, or winter mushroom, F. velutipes has been cultivated in China for both dietary and medicinal purposes since 800 CE. It was the second earliest mushroom to be cultivated, after Auricularia auricula (~600 AD) and before Lentinula edodes (~1000 AD). For a long time, Japan was the largest enoki mushroom producer in the world, until the 1990s when China took over the position.
2.2 Traditional Medicinal Use
Appreciated because of its health advantages, the enoki mushroom has been utilized in traditional Chinese and Japanese medication for hundreds of years as a tonic for liver disease, high cholesterol levels, stomach ailments, and high blood pressure. Traditional medicine systems used the enoki mushroom to heal digestive issues, alleviate constipation, treat liver disease, and regulate blood pressure.
Enoki has traditionally been used in Japan, China and Korea to make soups. In Japanese folk medicine, enoki was also incorporated into broths and teas. Folk medicine has long recognized mushrooms for their wide spectrum of therapeutic and prophylactic uses. Many medicinal mushrooms are important ingredients in Traditional Chinese Medicine, such as Flammulina velutipes.
It should be emphasised that traditional claims — such as curing stomach ulcers, liver disease, or reducing hypertension — predate controlled scientific investigation and rest on empirical observation rather than rigorous clinical evidence. These uses are recorded here solely as historical context.
3. Nutritional Composition
Similar to many other edible mushrooms, F. velutipes is consumed as a delicacy noted for the pleasant aroma and texture it gives to a dish. More importantly, consuming F. velutipes can provide key nutrients such as proteins, vitamins, minerals, unsaturated fatty acids and fiber.
Like many mushrooms, enokis are highly nutritious and rich in vitamins and minerals. These mushrooms are an excellent source of niacin and pantothenic acid, and are also good sources of thiamin, riboflavin, copper, folate, and phosphorus. They are also rich in vitamins (B-group, D), minerals (K, Se, Zn), and dietary fiber.
According to the literature, Flammulina velutipes contains biologically active components such as dietary fiber, polysaccharide, and mycosterol, whose effects in reducing blood sugar, blood pressure, and cholesterol have been documented in experimental studies. Dietary fiber is an active polysaccharide, which is part of the edible portion of F. velutipes and cannot be decomposed by lytic enzyme or digested in the human alimentary tract.
4. Key Bioactive Constituents and Mechanisms of Action
4.1 Polysaccharides
Flammulina velutipes exhibits a broad spectrum of biological activities, including antioxidant, anti-inflammatory, antitumor, immunomodulatory, and gut microbiota-regulating effects. These effects are primarily attributed to bioactive compounds such as polysaccharides, phenolic compounds, and sterols, and are mediated through the modulation of multiple signaling pathways, including NF-κB, MAPK, and PI3K/Akt.
Key polysaccharides identified in enokitake include flammulin and proflamin (acidic heteropolysaccharides), along with β-glucans, which are considered the primary pharmacologically active components. Another noteworthy polysaccharide, Flammulina velutipes polysaccharide I-A (FVP I-A), has been shown to reduce oxidative stress and stimulate the immune system to provide an enhanced immune response to pathogens.
FVP was found to be mainly composed of glucose, mannose, xylose, fucose, and galactose. FVP has been reported to have a wide range of bioactivities, including prebiotic, immunomodulatory, antioxidant, anti-osteoporosis, along with learning and memory-improving activities. However, most polysaccharides have low bioavailability and cannot be digested when administered orally, arriving largely unmetabolized in the colon, where they are likely degraded and utilized by the gut microflora.
4.2 FIP-fve (Fungal Immunomodulatory Protein)
FIP-fve is a fungal immunomodulatory protein (FIP), primarily extracted from the fruiting body, and has been widely studied for its immune-regulating, anticancer, and anti-inflammatory properties. FIP-fve is a fungal immunomodulatory protein purified from Flammulina velutipes. When examined for its effects on lymphocytes, FIP-fve exhibited potent mitogenic effects on human peripheral blood lymphocytes, inducing G1/G0 to S phase proliferation. T cells activated by FIP-fve show significant production and secretion of interferon-gamma (IFN-gamma) associated with intercellular adhesion molecule 1 expression. The p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580 can fully abolish the production of IFN-gamma induced by FIP-fve.
4.3 Proflamin
Proflamin, an acidic glycoprotein isolated from the mycelium, enhanced several immunosuppression processes and exhibited antiproliferative effects against various cancer cells. It was demonstrated to be able to prolong the lifespan of mice bearing B-16 melanoma and adenocarcinoma 755 tumor cells. When given as combination therapy along with vaccines or surgery, it also inhibited the growth of sarcoma S-180, L1210 leukemia ascite cells and Meth-A fibrosarcoma.
4.4 EA6 (Protein-Bound Polysaccharide)
Enokitake has high antitumor activity, and polysaccharides and a low molecular weight protein-bound polysaccharide (EA6) were isolated. It was demonstrated that EA6 was active against tumors when administered orally (p.o.), but not so effective by intraperitoneal (i.p.) injection. It proved to be especially useful by p.o. in combination with surgery and other antitumor agents. The antitumor effects of EA6, which are manifested by strengthening the specific and innate immunity, were shown to be mediated by CD4+ T cells.
4.5 Flammulin and Flammutoxin
Several proteins have been isolated and characterized from F. velutipes. Flammulin contains a total of 18 amino acids, while flammutoxin is a cytolytic protein rich in tryptophan, serine, and glycine but poor in sulfur-containing amino acids. From the aqueous extract of fruit bodies of F. velutipes, flammulin, an anti-tumor substance, was purified. Flammutoxin, a protein found in F. velutipes that is cytolytic and cardiotoxic when injected, has been shown to be non-toxic when absorbed orally.
4.6 Ergothioneine
Enoki extracts contain antioxidants such as the compound ergothioneine. Ergothioneine is a naturally occurring sulfur-containing amino acid and is one of the most potent antioxidant molecules found in mushrooms. Enokitake has antioxidants that rid the body of free radicals hence boosting the immune system, and one such antioxidant in the mushroom is ergothioneine.
4.7 Phenolic Compounds and Sterols
Polyphenol compounds such as quercetin, catechin, gallic acid ester, and caffeic acid ester can prevent cytotoxicity caused by H₂O₂, and the oxidative damage caused by anti-free radicals is also useful in reducing LDL oxidation, DNA damage, and the incidence of cancer. Fruiting body extracts from F. velutipes have been shown to effectively scavenge DPPH free radicals and display reducing power. Terpenoids including sterols such as ergosterol function as a precursor to vitamin D2. Mycosterol has the ability to reduce total cholesterol and LDL in the blood.
4.8 Velvetin and Lectins
Glycoproteins and peptides such as velvetin (a novel antifungal peptide), FVE (a protein-bound polysaccharide complex), and lectins with immunomodulatory properties have also been identified. A stable hemagglutinin isolated from the fruiting bodies of this mushroom inhibits proliferation of leukemia L1210 cells.
5. Scientific Evidence by Area of Use
5.1 Anticancer Activity
Epidemiological evidence: A study of 174,505 inhabitants of the Nagano area of Japan compared the cancer death rates among F. velutipes farmers with rates in the general population over a 15-year period (1972–86) and found that the F. velutipes farmers had a much lower death rate of 97.1 per 100,000, compared to 160.1 per 100,000 in the general population, with the suggestion that this was due to increased consumption of F. velutipes. Some studies, especially from Japan and China, have suggested lower cancer incidence rates in populations that consume large quantities of this mushroom, although confounding factors cannot be ruled out.
Preclinical evidence: Water-based extracts of F. velutipes were identified as novel anti-breast-cancer agents. They could markedly inhibit growth of both estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells, and the extract induced an exceptionally rapid apoptosis on both types of cancer cells. In a separate study of aqueous extracts from 20 mushrooms and three mushroom polysaccharides, the aqueous extract from F. velutipes, together with that from Pleurotus ostreatus, showed the highest level of cytotoxic activity against androgen-independent prostate cancer cells.
In vivo, EA6, a protein-bound polysaccharide isolated from the fruiting body of F. velutipes, augmented humoral immunity, cellular immunity, and IL-2 production in mice bearing Meth-A fibrosarcoma at 10 mg/kg; administration after surgery markedly inhibited growth of the rechallenged Meth-A solid tumour, while Proflamin (90% protein, 10% polysaccharide) isolated from the mycelium of F. velutipes abolished suppression of immunocompetence after cryosurgery at 10 mg/kg/day. Another protein from F. velutipes, Fve, protected mice against liver cancer through activation of both innate and adaptive immune responses when administered orally at a dose of 10 mg/kg.
Anti-HPV/antiviral animal evidence: Co-administration of Fve, a protein from F. velutipes, with immunization against HPV-16 led to 60% of mice remaining tumour-free 167 days after challenge with tumour cells compared to 20% of those receiving immunization alone. The co-immunized mice showed enhanced production of HPV-16 E7 oncoprotein-specific antibodies as well as expansion of HPV-16 E7-specific IFN-gamma-producing CD4⁺ and CD8⁺ T cells.
Evidence strength: Despite promising laboratory findings, there is a lack of robust human clinical trials demonstrating a clear and reproducible benefit for cancer patients. Most available data are preclinical, and the evidence for efficacy in humans is limited to a few small pilot studies or epidemiological observations. As such, F. velutipes cannot be considered an evidence-based treatment or a substitute for conventional cancer therapies at this time.
5.2 Immunomodulation
FIP-fve exhibited potent mitogenic effects on human peripheral blood lymphocytes, inducing G1/G0 to S phase proliferation. T cells activated by FIP-fve show significant production and secretion of IFN-gamma associated with intercellular adhesion molecule 1 expression. This is in vitro evidence from human cells, but does not constitute a clinical trial.
A crude polysaccharide derived from Flammulina velutipes (FVP), mainly consisting of glucose linked with β-glycosidic bonds, was administered to 6-week-old male ICR mice by gavage for five weeks to investigate effects on intestinal microbiota and immune response. The pH of the intestinal compartments decreased while short-chain fatty acid concentrations increased in FVP-fed groups in a dose-dependent manner. High-throughput sequencing revealed an enrichment in the diversity and an alteration in the composition of the fecal microbiota in the FVP-fed mice. A significant decrease in the Firmicutes/Bacteroidetes ratio and relative abundances of Lactobacillus and Akkermansia were related to energy absorption. The relative abundances of Porphyromonadaceae and Bacteroidaceae positively correlated with an increase in serum immunoglobulin and cytokines. These are animal studies; no comparable controlled human clinical trials have been published.
5.3 Gut Microbiota Modulation and Digestive Health
Flammulina velutipes polysaccharides (FVP) exhibit many biological activities, and researchers explored their composition and influence on human gut microflora composition and metabolites. FVP was used in vitro fermentation through human fecal inoculums, and 16S rRNA sequencing was used to assess the effects of FVP on the gut microbiota. FVP was shown to increase the relative abundances of Bifidobacteriaceae, as well as Bacteroidaceae, and remarkably decrease the numbers of genera Lachnospiraceae coupled with Enterococcaceae. The differential metabolites identified were mainly involved in glycerophospholipid metabolism, linoleic acid, and synthesis of unsaturated fatty acids. This is an in vitro fermentation study using human fecal inoculums, representing indirect but human-relevant evidence; controlled clinical trials in humans are absent.
Water-soluble dietary fiber from F. velutipes can be combined with cholesterol or cholic acid by adsorption, reducing the amount of cholic acid returned to the liver and increasing the metabolism of cholesterol and its transformation into cholic acid.
5.4 Hypolipidemic and Cardiovascular Effects
Male hamsters were subjected to lipid metabolism monitoring by adding 1%, 2%, and 3% FVP or FVE into their diets for a period of 8 weeks. The animal assay results showed that the 3% FVP and FVE groups had the lowest concentrations of TC (total cholesterol), TG (triacylglycerol), LDL, and LDL/HDL in the serum and liver (P < 0.05). F. velutipes contains rich dietary fiber, which accelerates the decomposition of cholesterol and hence can reduce TG, TC, and LDL levels in the blood and TG, TC, and phospholipid in the liver. Mycosterol has the ability to reduce total cholesterol and LDL in the blood. All available cardiovascular evidence originates from preclinical animal or in vitro studies; no published randomised controlled trials in humans were identified.
5.5 Antioxidant Activity
F. velutipes extract displayed antioxidant activity as high as 99.7% in DPPH assay conditions, and also showed a metal chelating ability. Studies have demonstrated that it exhibits a wide range of biological activities, including antioxidant effects. The ergothioneine content of enokitake contributes particularly to its antioxidant capacity. Evidence is primarily from in vitro assays; human clinical data is lacking.
5.6 Anti-inflammatory Effects
The anti-inflammatory effects of enokitake are primarily attributed to bioactive compounds such as polysaccharides, phenolic compounds, and sterols, and are mediated through the modulation of multiple signaling pathways, including NF-κB, MAPK, and PI3K/Akt. Evidence for anti-inflammatory activity is based on in vitro cell culture models and some rodent experiments; no human clinical trials specifically addressing inflammatory outcomes have been identified.
5.7 Skin Health
One small-scale human randomized controlled trial has investigated enokitake and skin health. A new variety of Flammulina velutipes (Oki-Shirayuki 919), which contained more glucosylceramide than existing varieties, was explored to ascertain whether its components have functions of nutricosmetics, focusing on physiological effects for enhancing human skin condition such as moisturizing or barrier functions. A randomized, double-blind, placebo-controlled clinical study was performed between January and March 2022. Among healthy men and women (n = 30) aged 20 to 59 years, the test group (n = 15) took a test product which included F. velutipes dry powder, and the placebo group (n = 15) took a placebo. Only skin hydration showed a significant difference compared to the placebo, while transepidermal water loss (TEWL) did not reach significance. This was described as the first study to clinically evaluate the effect of oral intake of F. velutipes Oki-Shirayuki 919 on healthy adults' skin condition, and provides some new clinical evidence along with indicating limitations and future challenges. The small sample size (n = 30) limits generalisability.
5.8 Antimicrobial Activity
Proteins from F. velutipes show direct antiviral activity, including ribosome-inactivating activity and inhibition of HIV-1 reverse transcriptase, beta-glucosidase and beta-glucuronidase. These are in vitro observations only. Compounds in enokitake have been demonstrated to exhibit antibacterial activity in cell culture-based studies.
5.9 Cognitive and Neuroprotective Effects
A study evaluated the cognitive-enhancing effect of Flammulina velutipes polysaccharides (FVP) combined with ginsenosides on D-galactose-induced Alzheimer's disease rats. Results of the Morris water maze test suggested that the cognitive ability of AD rats was significantly elevated after combined treatment with FVP and ginsenosides. Moreover, the antioxidant effect was also elevated as reflected by increased levels of superoxide dismutase, catalase, and glutathione peroxidase and decreased levels of malondialdehyde in the combination group. This is animal evidence only. No human clinical trials investigating cognition as a primary endpoint have been published in the available literature.
6. Body Systems Associated with Enokitake
Compounds in Flammulina velutipes have been demonstrated to exhibit biological activities relevant to multiple body systems, including antitumour and anticancer activities, anti-atherosclerotic and thrombosis inhibition activity, antihypertensive and cholesterol-lowering effects, anti-aging and antioxidant properties, ability to aid with restoring memory and overcoming learning deficits, anti-inflammatory, immunomodulatory, antibacterial, ribosome inactivation and melanosis inhibition. The body systems most prominently addressed in the scientific literature include:
- Immune system: Immunomodulatory effects mediated by FIP-fve, polysaccharides, and EA6 have been studied in cell culture and rodent models.
- Digestive system / gut microbiome: Polysaccharides act as prebiotics, modulating microbiota composition and short-chain fatty acid production.
- Cardiovascular system: Hypolipidemic and potential antihypertensive effects studied in animal models.
- Oncology: Anticancer and anti-tumor activity studied in vitro and in murine models, with epidemiological observations in Japanese farming populations.
- Skin: Glucosylceramide content linked to skin barrier function in one small human RCT.
- Nervous system / cognition: Polysaccharide fractions have shown neuroprotective effects in rodent Alzheimer's models.
- Antioxidant / anti-aging: DPPH scavenging and ergothioneine content documented in vitro.
7. Dosage Forms and Reported Dosages
The fruiting body of F. velutipes contains high levels of therapeutically active proteins at a reasonable cost and is the preferred dosage form in most cases, with 3–5 g dried fruiting body equating to 30–50 g fresh mushroom. This is a reference range cited in the mycological literature, not from a clinical pharmacokinetic study.
In preclinical research, the following dosages were employed:
- EA6 was administered at 10 mg/kg and Proflamin at 10 mg/kg/day in mouse tumour models.
- Fve was orally administered in murine models at a dose of 10 mg/kg.
- Hamsters were given 1%, 2%, and 3% FVP or FVE added to their diets for 8 weeks to assess lipid metabolism effects.
In the one identified human RCT (skin study), a randomized, double-blind, placebo-controlled clinical study was performed in healthy men and women (n = 30) aged 20 to 59 years; the test group (n = 15) took a test product which included F. velutipes dry powder. The exact gram dosage of dry powder administered per day was not specified in the available abstract.
No established clinical dosage guidelines have been issued by regulatory bodies such as the WHO, EMA, or EFSA for enokitake as a dietary supplement, and no pharmacopoeial monograph was identified in available sources.
8. Safety Considerations
8.1 General Safety Profile
It has no known toxic effect on the human body and is very beneficial to human health at food consumption levels, according to one PMC-indexed review. One notable consideration is that the chemical constituents of the mushroom can vary dramatically depending on age, genetics, and type of processing (if any). It is possible, therefore, that not all enokitake products share the same medical usefulness.
8.2 Flammutoxin — Cardiotoxic Protein
Flammutoxin, a protein found in F. velutipes that is cytolytic and cardiotoxic when injected, has been shown to be non-toxic when absorbed orally. Nonetheless, a rodent study raised concerns about high-dose consumption: F. velutipes consumption caused increased activities of plasma creatine kinase and the MB-fraction of creatine kinase at 6–9 g/kg/day in mice, indicating potentially deleterious effects on both skeletal and cardiac muscle. The plasma total and high-density lipoprotein cholesterol concentrations (at 9 g/kg/day) and white blood cell and lymphocyte counts (at 6–9 g/kg/day) decreased. Although the cholesterol-lowering properties of F. velutipes can be beneficial, the previously unexamined, potentially hazardous side effects of mushroom consumption (myo- and cardiotoxicity) should be thoroughly investigated before recommending this mushroom species as a health-promoting food item. It is important to note that these findings were in mice at very high doses; their relevance to normal human dietary consumption remains unestablished.
8.3 Allergic Reactions and Anaphylaxis
Published case reports in peer-reviewed Japanese allergy journals document IgE-mediated hypersensitivity reactions to enokitake. Enokitake is a common edible mushroom in Japan. In one documented case, a seventeen-year-old woman experienced anaphylaxis after the ingestion of sukiyaki containing enokitake. A skin prick test was positive and oral food challenge was positive, inducing anaphylaxis. Western blotting identified three enokitake protein bands (18 kDa, 39 kDa, 50 kDa) that reacted specifically with the patient's IgE.
In a second case, Western blotting with enokitake extracts and the patient's serum identified an enokitake protein band at 75 kDa that reacted specifically with the patient's IgE. This band was identified as a novel enokitake allergen distinct from those previously reported. These cases indicate that multiple distinct allergens exist within the mushroom's protein profile.
8.4 Cross-reactivity with Other Mushrooms
In one reported hypersensitivity case, skin prick tests to other mushrooms (shiitake, shimeji, and eringi) were also all positive, suggesting possible cross-reactivity across multiple edible mushroom species in sensitised individuals.
8.5 Listeria monocytogenes Contamination Risk
Enoki mushrooms were recalled in Canada due to the possible presence of L. monocytogenes in 2019. Consumption of L. monocytogenes-contaminated enoki mushrooms has been associated with multistate human listeriosis cases, affecting 30 patients and causing four deaths over three years in the United States. Recent outbreaks and product recalls highlight the need for stringent food safety measures and enhanced monitoring to mitigate the risks associated with L. monocytogenes contamination during enoki mushroom production and distribution. The first known listeriosis outbreak linked to enoki mushrooms, imported from the Republic of Korea, occurred from 2016 to 2020, with 48 ill people identified from the United States and Canada, which led to a coordinated response by the United States, Canada, France, and Australia. This is a food safety hazard specifically associated with raw or inadequately handled enoki mushrooms and is unrelated to their bioactive constituents.
Summary of Evidence Quality
The available evidence collectively indicates that F. velutipes represents a promising candidate for the development of functional foods and pharmaceutical formulations, and the review emphasises its therapeutic potential and provides valuable insights to guide future medicinal research. However, it must be stated plainly that the overwhelming majority of mechanistic and efficacy data for enokitake comes from in vitro cell culture studies and rodent models. Human clinical trial evidence is extremely limited: only one small (n = 30) randomised double-blind placebo-controlled trial in humans was identified in the published literature (on skin hydration), and key areas such as cancer, lipid lowering, immunomodulation, and cognitive function lack any published controlled human clinical trials. Epidemiological observations from Nagano, Japan, are suggestive but do not establish causation due to the presence of uncontrolled confounders.
References
Go back